Nuwellis decoration

Newsroom

Newsroom

Press Releases

Date Title and Summary Additional Formats
June 29, 2022
Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF
REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOLIS , June 29, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the company’s pivotal REVERSE-HF
June 14, 2022
Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas
Pediatric Segment Growth Continues at 36% CAGR MINNEAPOLIS , June 14, 2022 (GLOBE NEWSWIRE) -- Improving access to life-saving fluid management therapies is a commitment by which Nuwellis, Inc. (Nasdaq: NUWE) stands. The company today announced its Aquadex SmartFlow® system is now available at two
May 17, 2022
Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
MINNEAPOLIS , May 17, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that the Company’s 2022 Annual Meeting of Stockholders, on May 17, 2022 at 2:00 p.m. , was convened and adjourned, without any business being conducted, due to lack of the required quorum.
May 10, 2022
Nuwellis, Inc. Announces First Quarter 2022 Financial Results
MINNEAPOLIS , May 10, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the first quarter ended March 31, 2022 , which included the following highlights: Generated $1.9 million in total revenue for the first quarter 2022, up 17% sequentially from the fourth
May 9, 2022
Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting
New Data Adds to the Growing Body of Research Supporting the Negative Impact of Fluid Overload, Therapies to Prevent Kidney Injury and the Use of Ultrafiltration for Varying Patient Populations MINNEAPOLIS , May 09, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc.
April 12, 2022
Nuwellis, Inc. To Announce First Quarter 2022 Financial Results on May 10, 2022
MINNEAPOLIS , April 12, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 . The company will host a conference call and webcast at 9:00 AM ET , during which management will discuss the
March 15, 2022
Nuwellis Announces IRB Approval to Begin Its REVERSE-HF Clinical Study
The REVERSE-HF study will evaluate ultrafiltration therapy for heart failure patients suffering from fluid overload MINNEAPOLIS , March 15, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced it has received independent Institutional Review Board (IRB) approval for the trial
March 1, 2022
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
MINNEAPOLIS , March 01, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the fourth quarter and full year ended December 31, 2021 , which included the following highlights: Generated $1.6 million in total revenue for the fourth quarter 2021, 19.6% below the
February 22, 2022
Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MINNEAPOLIS , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective February 22, 2022 , the independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to five individuals entering into employment with the
February 17, 2022
Nuwellis Initiates REVERSE-HF Study to Evaluate Ultrafiltration for Heart Failure Patients with Fluid Overload
REVERSE-HF will evaluate rehospitalizations and survival when using the Aquadex therapy MINNEAPOLIS , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the company will evaluate the clinical outcomes and economic value of its Aquadex ® therapy in comparison to
Displaying 1 - 10 of 12

Upcoming Events

More events are coming soon.
jump